FY2026 EPS Estimates for Celcuity Boosted by HC Wainwright

Celcuity, Inc. (NASDAQ:CELC - Free Report) - Equities research analysts at HC Wainwright increased their FY2026 earnings estimates for Celcuity in a report issued on Wednesday, October 22nd. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($4.06) per share for the year, up from their prior estimate of ($4.15). HC Wainwright has a "Buy" rating and a $77.00 price objective on the stock. The consensus estimate for Celcuity's current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity's FY2027 earnings at $1.36 EPS, FY2028 earnings at $4.84 EPS and FY2029 earnings at $8.18 EPS.

A number of other equities analysts have also weighed in on CELC. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research report on Monday. Leerink Partners increased their price target on Celcuity from $28.00 to $60.00 and gave the stock an "outperform" rating in a research note on Monday, July 28th. Stifel Nicolaus started coverage on Celcuity in a research note on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company. Guggenheim began coverage on Celcuity in a research note on Monday, September 22nd. They set a "buy" rating on the stock. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Celcuity in a report on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $65.50.

Celcuity Price Performance

Shares of Celcuity stock opened at $70.57 on Friday. Celcuity has a one year low of $7.57 and a one year high of $83.00. The stock's fifty day moving average is $53.28 and its 200 day moving average is $29.09. The stock has a market cap of $2.99 billion, a P/E ratio of -20.46 and a beta of 0.70. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.14).

Hedge Funds Weigh In On Celcuity

Several hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company's stock worth $35,000 after purchasing an additional 1,167 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company's stock valued at $74,000 after buying an additional 3,766 shares during the period. Avanza Fonder AB purchased a new stake in Celcuity in the 3rd quarter valued at about $79,000. AlphaQuest LLC boosted its position in Celcuity by 176.3% in the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after buying an additional 4,522 shares during the period. Finally, Perkins Capital Management Inc. purchased a new stake in Celcuity in the 1st quarter valued at about $115,000. 63.33% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares of the company's stock, valued at $5,497,500. This trade represents a 44.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.77% of the stock is owned by insiders.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.